Is the revascularisation strategy and outcome different in patients with acute coronary syndrome in COVID-19 pandemic era: a tertiary centre experience

References

• World Health Organization. Coronavirus disease 2019. Situation report. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus2019/situation-reports/. Accessed April 13, 2020.
   Google Scholar
• Sulemane S, Baltabaeva A, Barron AJ, et al. Acute pulmonary embolism in conjunction with intramural right ventricular thrombus in a SARS-CoV-2-positive patient. Eur Heart J Cardiovasc Imaging. 2020;21(9):1054.
   Web of Science ®Google Scholar
• Meyer P, Degrauwe S, Delden CV, et al. Typical takotsubo syndrome triggered by SARS-CoV-2 infection. Eur Heart J. 2020;41(19):1860.
   Web of Science ®Google Scholar
• Siddamreddy S, Thotakura R, Dandu V, et al. Corona virus disease2019 (COVID-19) presenting as acute ST elevation myocardial infarction. Cureus. 2020;22(12):e7782.
   Google Scholar
• Sanchez-Recalde A, Solano-Lo ́Pez J, Miguelena-Hycka J, et al. COVID-19 and cardiogenic shock. Different cardiovascular presentations with high mortality. Rev Esp Cardiol. 2020;73(8):669–672.
   Web of Science ®Google Scholar
• Kang Y, Chen T, Mui D, et al. Cardiovascular manifestations and treatment considerations in COVID-19. Heart. 2020;106(15):1132–1141.
   PubMed Web of Science ®Google Scholar
• Yavuz SŞ. Cardiovascular system and COVID-19. Turk Kardiyol Dern Ars. 2020;48(7):635–639.
   Web of Science ®Google Scholar
• Levi M, Thachil J, Iba T, et al. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438–40–e440.
   Web of Science ®Google Scholar
• Bikdeli B, Madhavan MV, Jimenez D, Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(23):2950–2973.
   PubMed Web of Science ®Google Scholar
• Nishiga M, Wang DW, Han Y, et al. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543–558.
   PubMed Web of Science ®Google Scholar
• Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017–1032.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, China Medical Treatment Expert Group for Covid-19, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720.
   PubMed Web of Science ®Google Scholar
• Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18(7):1747–1751.
   PubMed Web of Science ®Google Scholar
• Çinier G, Hayıroğlu M, Pay L, et al. Effect of the COVID-19 pandemic on access to primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Turk Kardiyol Dern Ars. 2020;48(7):640–645.
   PubMed Web of Science ®Google Scholar
• Garcia S, Stanberry L, Schmidt C, et al. Impact of COVID-19 pandemic on STEMI care: an expanded analysis from the United States. Catheter Cardiovasc Interv. 2020;98(2):217–222. [Epub ahead of print].
   Web of Science ®Google Scholar
• De Luca G, Suryapranata H, Ottervanger JP, et al. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation. 2004;109(10):1223–1225.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93(5):879–888.
   Google Scholar
• Gibson CM, de Lemos JA, Murphy SA, et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001;103(21):2550–2554.
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al.; ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177.
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Sousa-Uva M, Ahlsson A, et al.; ESC Scientific Document Group. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165.
   PubMed Web of Science ®Google Scholar
• Choudry FA, Hamshere SM, Rathod KS, et al. High thrombus burden in patients with COVID-19 presenting with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2020;76(10):1168–1176. Epub 2020 Jul 14.
   PubMed Web of Science ®Google Scholar
• Alaarag A, Hassan T, Samir S, et al. Clinical and angiographic characteristics of patients with STEMI and confirmed diagnosis of COVID-19: an experience of Tanta University Hospital. Egypt Heart J. 2020;72(1):68.
   Google Scholar
• Showkathali R, Yalamanchi R, Sankeerthana MP, et al. Acute coronary syndrome admissions and outcome during COVID-19 pandemic – report from large tertiary centre in India. Indian Heart J. 2020;72(6):599–602.
   Google Scholar
• Zhang ZJ, Marroquin OC, Stone RA, et al. Differential effects of post-dilation after stent deployment in patients presenting with and without acute myocardial infarction. Am Heart J. 2010;160(5):979–986.e1.
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Windecker S, Mehran R, et al. Academic research consortium clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–2351.
   PubMed Web of Science ®Google Scholar
• Atri D, Siddiqi HK, Lang JP, et al. COVID-19 for the cardiologist: basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies. JACC Basic Transl Sci. 2020;5(5):518–536.
   PubMedGoogle Scholar
• Vivas D, Roldán V, Esteve-Pastor MA, et al. Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID-19. Posicionamiento del grupo de trabajo de trombosis cardiovascular de la sociedad española de cardiología. Rev Esp Cardiol. 2020;73(9):749–757.
   Web of Science ®Google Scholar
• Prieto-Lobato A, Ramos-Martínez R, Vallejo-Calcerrada N, et al. A case series of stent thrombosis during the COVID-19 pandemic. JACC Case Rep. 2020;2(9):1291–1296.
   PubMedGoogle Scholar
• Kretchy IA, Asiedu-Danso M, Kretchy JP. Medication management and adherence during the COVID-19 pandemic: perspectives and experiences from low-and middle-income countries. Res Social Adm Pharm. 2021;17(1):2023–2026.
   PubMed Web of Science ®Google Scholar
• Zwart B, Godschalk TC, Kelder JC, et al. High risk of stent thrombosis in the first 6 months after coronary stenting: do not discontinue clopidogrel early after ACS. J Interv Cardiol. 2017;30(5):421–426.
   Web of Science ®Google Scholar
• Little CD, Kotecha T, Candilio L, et al. COVID-19 pandemic and STEMI: pathway activation and outcomes from the pan-London heart attack group. Open Heart. 2020;7(2):e001432.
   Web of Science ®Google Scholar
• Claeys MJ, Argacha JF, Collart P, et al. Impact of COVID-19-related public containment measures on the ST elevation myocardial infarction epidemic in Belgium: a nationwide, serial, cross-sectional study. Acta Cardiol. 2020;30:1–7.
   Google Scholar
• Adlan AM, Lim VG, Dhillon G, et al. Impact of COVID-19 on primary percutaneous coronary intervention centres in the UK: a survey. Brit J Cardiol. 27(2):51–54.
   Google Scholar
• Rodriguez-Leor O, Cid-Alvarez B. ST-segment elevation myocardial infarction care during COVID-19: losing sight of the forest for the trees. JACC Case Rep. 2020;2(10):1625–1627.
   Google Scholar
• ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349–360.
   PubMed Web of Science ®Google Scholar
• Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361(9351):13–20.
   PubMed Web of Science ®Google Scholar
• Biancari F, Gudbjartsson T, Heikkinen J, et al. Comparison of 30-day and 5-year outcomes of percutaneous coronary intervention versus coronary artery bypass grafting in patients aged ≤50 years (the coronary aRtery diseAse in younG adultS study). Am J Cardiol. 2014;114(2):198–205. amjcard.2014.04.025.
   Web of Science ®Google Scholar
• Solano-Lopez J, Zamorano JL, Sanz AP, et al. Risk factors for in-hospital mortality in patients with acute myocardial infarction during the COVID-19 outbreak. Rev Esp Cardiol (Engl Ed.). 2020;73(12):985–993.
   Web of Science ®Google Scholar